HUP0101739A3 - Extended release tiagabine formulations with reduced side-effects - Google Patents

Extended release tiagabine formulations with reduced side-effects

Info

Publication number
HUP0101739A3
HUP0101739A3 HU0101739A HUP0101739A HUP0101739A3 HU P0101739 A3 HUP0101739 A3 HU P0101739A3 HU 0101739 A HU0101739 A HU 0101739A HU P0101739 A HUP0101739 A HU P0101739A HU P0101739 A3 HUP0101739 A3 HU P0101739A3
Authority
HU
Hungary
Prior art keywords
effects
extended release
reduced side
formulations
release tiagabine
Prior art date
Application number
HU0101739A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HUP0101739A2 publication Critical patent/HUP0101739A2/hu
Publication of HUP0101739A3 publication Critical patent/HUP0101739A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
HU0101739A 1998-01-22 1999-01-22 Extended release tiagabine formulations with reduced side-effects HUP0101739A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7213098P 1998-01-22 1998-01-22
PCT/US1999/001242 WO1999037302A1 (en) 1998-01-22 1999-01-22 Extended release tiagabine formulations with reduced side-effects

Publications (2)

Publication Number Publication Date
HUP0101739A2 HUP0101739A2 (hu) 2002-03-28
HUP0101739A3 true HUP0101739A3 (en) 2002-10-28

Family

ID=22105780

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101739A HUP0101739A3 (en) 1998-01-22 1999-01-22 Extended release tiagabine formulations with reduced side-effects

Country Status (23)

Country Link
US (1) US20070053980A1 (hu)
EP (1) EP1049470B1 (hu)
JP (1) JP2002501022A (hu)
KR (1) KR20010034313A (hu)
CN (1) CN1145484C (hu)
AR (1) AR018041A1 (hu)
AT (1) ATE350035T1 (hu)
AU (1) AU2239599A (hu)
BG (1) BG104692A (hu)
CA (1) CA2318448A1 (hu)
CO (1) CO4970814A1 (hu)
DE (1) DE69934670D1 (hu)
HU (1) HUP0101739A3 (hu)
IL (1) IL137324A0 (hu)
NO (1) NO20003677L (hu)
NZ (1) NZ505725A (hu)
PL (1) PL194595B1 (hu)
SA (1) SA99200204B1 (hu)
SK (1) SK11072000A3 (hu)
TR (2) TR200002102T2 (hu)
TW (1) TW585787B (hu)
WO (1) WO1999037302A1 (hu)
ZA (1) ZA99407B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872734B2 (en) 2000-10-20 2005-03-29 Abbott Laboratories Use of tiagabine for treatment of diabetic neuropathy and migraine
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JP3195360B2 (ja) * 1995-05-05 2001-08-06 ノボ ノルディスク アクティーゼルスカブ チアガビン塩酸塩を含有する医薬組成物およびその製法
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
EP0991409B1 (en) * 1997-08-01 2002-01-30 ELAN CORPORATION, Plc Controlled release pharmaceutical compositions containing tiagabine
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting

Also Published As

Publication number Publication date
CO4970814A1 (es) 2000-11-07
NZ505725A (en) 2003-01-31
CA2318448A1 (en) 1999-07-29
NO20003677L (no) 2000-09-20
ATE350035T1 (de) 2007-01-15
EP1049470B1 (en) 2007-01-03
KR20010034313A (ko) 2001-04-25
TR200002102T2 (tr) 2000-12-21
HUP0101739A2 (hu) 2002-03-28
AU2239599A (en) 1999-08-09
PL342767A1 (en) 2001-07-02
BG104692A (en) 2001-05-31
CN1293571A (zh) 2001-05-02
ZA99407B (en) 1999-07-20
EP1049470A1 (en) 2000-11-08
SA99200204B1 (ar) 2006-10-11
DE69934670D1 (de) 2007-02-15
AR018041A1 (es) 2001-10-31
US20070053980A1 (en) 2007-03-08
TR200505223T2 (tr) 2006-04-21
JP2002501022A (ja) 2002-01-15
TW585787B (en) 2004-05-01
WO1999037302A1 (en) 1999-07-29
NO20003677D0 (no) 2000-07-18
PL194595B1 (pl) 2007-06-29
CN1145484C (zh) 2004-04-14
SK11072000A3 (sk) 2001-01-18
IL137324A0 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
DE59902573D1 (en) Dihydropyrimidine
SG77243A1 (en) Ziprasidone formulations
HK1033649A1 (en) Extended release dosage form
GB9804013D0 (en) Formulations
GB0029386D0 (en) Not known at present
GB0029389D0 (en) Not known at present
GB0014805D0 (en) Glassbreaker (2)
CZ2000495A3 (cs) Oběžné kolo
GB9907771D0 (en) Braking accumulator-accelerator
HUP0101739A3 (en) Extended release tiagabine formulations with reduced side-effects
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
EP1210152A4 (en) SKATES EQUIPPED WITH BLADES WITH ISOMETRIC CASTERS
AU2002325404A1 (en) Extended Release Tiagabine Formulations with Reduced Side-effects
GB9916162D0 (en) Runners
PL344600A1 (en) Adenosine a3
GB2354013B (en) W C flush
GB9913589D0 (en) Release sub
GB9825271D0 (en) Release flap
GB9910118D0 (en) Formulations
EG22401A (en) Set 3c1-strong
PL342404A1 (en) Nucleosides
TW359960U (en) Improved structure for undergarment
GB9810143D0 (en) Parasiticidal formulations
TW410560U (en) Improved pin structure

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees